Flag of the European Union EU Clinical Trials Register Help

Clinical trials for fluoxetine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: fluoxetine. Displaying page 4 of 4.
    « Previous 1  2  3  4 
    EudraCT Number: 2016-004422-42 Sponsor Protocol Number: ESKETINSUI2002 Start Date*: 2017-10-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Restarted) BE (Completed) PL (Completed) IT (Completed) BG (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021215-16 Sponsor Protocol Number: H9P-MC-LNBQ Start Date*: 2011-02-17
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major De...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-013420-23 Sponsor Protocol Number: F1J-US-HMGO Start Date*: 2009-11-09
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005282-22 Sponsor Protocol Number: 42847922MDD2001 Start Date*: 2017-10-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021214-39 Sponsor Protocol Number: H9P-MC-LNBM Start Date*: 2010-12-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Placebo-controlled, Double-blind Study of LY2216684 Fixed-dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responder...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-020726-18 Sponsor Protocol Number: H9P-MC-LNBO Start Date*: 2011-01-17
    Sponsor Name:Eli Lilly and Company
    Full Title: Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptak...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004884-30 Sponsor Protocol Number: P13-04/BP1.4979 Start Date*: 2017-12-07
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004645-36 Sponsor Protocol Number: TMP-2501-2019-2 Start Date*: 2021-05-31
    Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)
    Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER)
    Medical condition: Drug-induced elevated liver enzymes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024668 Liver damage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021216-41 Sponsor Protocol Number: H9P-MC-LNBR(a) Start Date*: 2011-01-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002869-18 Sponsor Protocol Number: Start Date*: 2019-09-04
    Sponsor Name:Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
    Full Title: A randomised, double-blind, placebo controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression.
    Medical condition: Bipolar disorder (BD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10012386 Depression mental LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-000399-25 Sponsor Protocol Number: ALK5461-206 Start Date*: 2014-07-09
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024632-42 Sponsor Protocol Number: H9P-MC-LNBN Start Date*: 2011-05-05
    Sponsor Name:Eli Lilly and Company
    Full Title: LY2216684 compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
    Medical condition: major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SK (Completed) GR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-004888-54 Sponsor Protocol Number: E2020-G000-326 Start Date*: 2007-12-07
    Sponsor Name:Eisai Ltd
    Full Title: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) LT (Completed) ES (Completed) AT (Completed) DK (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:33:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA